Prognostic significance of downregulated expression of programmed cell death 5 in chondrosarcoma

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 838-843

  Chen, Changbao ^a   Zhou, Hua ^a   Xu, Lanjun ^b,c   Liu, Xiaoguang ^a   Liu, Zhongjun ^a   Ma, Dalong ^b,c   Chen, Yingyu ^b,c   Ma, Qingjun ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

chondrosarcoma; prognostic significance; Programmed Cell Death 5

Indexed keywords

LYMPHOCYTE ANTIGEN; MESSENGER RNA; PROGRAMMED CELL DEATH 5; UNCLASSIFIED DRUG;

ARTICLE; CARTILAGE TUMOR; CHONDROSARCOMA; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BONE AND BONES; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHONDROSARCOMA; DOWN-REGULATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 78649654388     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21730     Document Type: Article

References (26)

1. Bertoni F, Bacchini P, Hogendoorn PCW:, Chondrosarcoma. In:, Fletcher CDM, Unni KK, Mertens F, editors. World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002; pp 247-251.
2. Rozeman LB, Cleton-Jansen AM, Hogendoorn PC:, Pathology of primary malignant bone and cartilage tumours. Int Orthop 2006; 30: 437-444.
3. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al.: The clinical approach towards chondrosarcoma. Oncologist 2008; 13: 320-329.
4. Wunder JS, Nielsen TO, Maki RG, et al.: Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007; 8: 513-524.
5. Riedel RF, Larrier N, Dodd L, et al.: The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009; 10: 94-106.
6. Papachristou DJ, Papavassiliou AG:, Osteosarcoma and chondrosarcoma: New signaling pathways as targets for novel therapeutic interventions. Int J Biochem Cell Biol 2007; 39: 857-862.
7. Liu H, Wang Y, Zhang Y, et al.: TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun 1999; 254: 203-210.
8. Wang Y, Li X, Wang L, et al.: An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci 2004; 117: 1525-1532.
9. Chen Y, Sun R, Han W, et al.: Nuclear translocation of PDCD5 (TFAR19): An early signal for apoptosis ? FEBS Lett 2001; 509: 191-196.
10. Xu L, Chen Y, Song Q, et al.: PDCD5 interacts with Tip60 and functions as a cooperator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia 2009; 11: 345-354.
11. Ma X, Ruan G, Wang Y, et al.: Two single-nucleotide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5 regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population. Clin Cancer Res 2005; 11: 8592-8599.
12. Spinola M, Meyer P, Kammerer S, et al.: Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. J Clin Oncol 2006; 24: 1672-1678.
13. Li H, Wang Q, Gao F, et al.: Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol Rep 2008; 20: 573-579.
14. Yang YH, Zhao M, Li WM, et al.: Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis 2006; 11: 993-1001.
15. Ruan GR, Qin YZ, Chen SS, et al.: Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk Res 2006; 30: 1159-1165.
16. Evans HL, Ayala AG, Romsdahl MM:, Prognostic factors in chondrosarcoma of bone: A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977; 40: 818-831.
17. Enneking WF, Spanier SS, Goodman MA:, A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 2003; 415: 4-18.
18. Rui M, Chen YY, Zhang YM, et al.: Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. Life Sci 2002; 71: 1771-1778.
19. Chen LN, Wang Y, Ma DL, et al.: Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression. Apoptosis 2006; 11: 101-111.
20. Lee FY, Mankin HJ, Fondren G, et al.: Chondrosarcoma of bone: An assessment of outcome. J Bone Joint Surg Am 1999; 81: 326-338.
21. Sanerkin NG, Gallagher P:, A review of the behaviour of chondrosarcoma of bone. J Bone Joint Surg Br 1979; 61: 395-400.
22. Sheth DS, Yasko AW, Johnson ME, et al.: Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer 1996; 78: 745-750.
23. York JE, Berk RH, Fuller GN, et al.: Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg 1999; 90: 73-78.
24. Bergh P, Gunterberg B, Meis-Kindblom JM, et al.: Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: A center-based study of 69 cases. Cancer 2001; 91: 1201-1212.
25. Rozeman LB, Hogendoorn PC, Bovee JV:, Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn 2002; 2: 461-472.
26. Chen C, Zhou H, Xu L, et al.: Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo. Apoptosis 2010; 15: 805-813.